Importantly, these results are in line with previous reports indicating that increased expression of thymidine kinase-1 (TK1), an enzyme of the pyrimidine salvage pathway, correlates with poor prognosis in breast cancer patients treated with palbociclib [52,53,54,55]. Here, TK1 is linked to breast carcinoma.